GlassScriptPhysician profile
Abraham Masara
NPI 1780065953
$6,681.65
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,013 · 2022: $1,770 · 2023: $2,697 · 2024: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,898.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,699.01 | 2021-2024 | Caplyta |
| Alkermes, INC. | $679.06 | 2021-2024 | Aristada, Lybalvi |
| Indivior INC. | $666.57 | 2021-2024 | Perseris, Sublocade |
| Teva Pharmaceuticals USA, INC. | $594.66 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $560.20 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $542.20 | 2021-2022 | |
| Lundbeck LLC | $370.41 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $327.12 | 2021-2024 | Spravato, Invega, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $256.81 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $233.54 | 2021-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $213.12 | 2021-2023 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $199.25 | 2022-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $102.07 | 2022-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $55.97 | 2022-2024 | |
| Braeburn INC. | $46.39 | 2023 | Brixadi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $41.31 | 2024 | |
| Neurocrine Biosciences, INC. | $36.67 | 2024 | Ingrezza |
| Corium, LLC | $22.29 | 2022 | |
| Almatica Pharma LLC | $17.83 | 2023 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $17.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Masara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.